TR200103183T2 - Amin türevi bileşimler - Google Patents

Amin türevi bileşimler

Info

Publication number
TR200103183T2
TR200103183T2 TR2001/03183T TR200103183T TR200103183T2 TR 200103183 T2 TR200103183 T2 TR 200103183T2 TR 2001/03183 T TR2001/03183 T TR 2001/03183T TR 200103183 T TR200103183 T TR 200103183T TR 200103183 T2 TR200103183 T2 TR 200103183T2
Authority
TR
Turkey
Prior art keywords
amine derivative
derivative compositions
hydrogen
hyperlipemia
arteriosclerosis
Prior art date
Application number
TR2001/03183T
Other languages
English (en)
Inventor
Fujita Takashi
Wada Kunio
Oguchi Minoru
Honma Hidehito
Fujiwara Toshihiko
Original Assignee
Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited
Publication of TR200103183T2 publication Critical patent/TR200103183T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Diyabet, hiperlipemi, arterioskleroz, kanser vs için terapötik ve/veya önleyici maddeler olarak faydali olan ve R1' in tercihe göre ikameli karbamoil veya benzeri; R2' nin hidrojen veya R3' ün C1-C10 alkil vb. ; W1, W2 ve W3 her birinin ayri ayri bir tekli bag veya C1-C8 alkilen; X, Y ve Q' nun sülfür vb.; Z' nin =CH- vb.; Ar' nin benzen halkasi, vb. ve L' nin hidrojen vb oldugu, genel formül (I) ile gösterilen amin türevleri veya farmakolojik olarak kabul edilebilir tuzlari.
TR2001/03183T 1999-04-07 2000-04-06 Amin türevi bileşimler TR200103183T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9998199 1999-04-07

Publications (1)

Publication Number Publication Date
TR200103183T2 true TR200103183T2 (tr) 2002-05-21

Family

ID=14261854

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03183T TR200103183T2 (tr) 1999-04-07 2000-04-06 Amin türevi bileşimler

Country Status (24)

Country Link
US (1) US6562849B1 (tr)
EP (1) EP1167366B1 (tr)
KR (1) KR100588284B1 (tr)
CN (1) CN1162427C (tr)
AT (1) ATE466861T1 (tr)
AU (1) AU757729B2 (tr)
BR (1) BR0009594A (tr)
CA (1) CA2369971A1 (tr)
CZ (1) CZ300691B6 (tr)
DE (1) DE60044342D1 (tr)
ES (1) ES2343104T3 (tr)
HK (1) HK1039940B (tr)
HU (1) HUP0200996A3 (tr)
ID (1) ID30498A (tr)
IL (2) IL145759A0 (tr)
MX (1) MXPA01010108A (tr)
NO (1) NO321158B1 (tr)
NZ (1) NZ514662A (tr)
PL (1) PL351878A1 (tr)
RU (1) RU2221796C2 (tr)
TR (1) TR200103183T2 (tr)
TW (1) TW550264B (tr)
WO (1) WO2000061581A1 (tr)
ZA (1) ZA200108174B (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033494A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Derive de benzimidazole
WO2003032988A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Composition pharmaceutique
AU2003220855A1 (en) * 2002-04-01 2003-10-13 Sankyo Company, Limited Medicinal antitumor composition
CN1307150C (zh) 2002-05-08 2007-03-28 拜耳医药保健股份公司 羟基四氢－萘基脲衍生物
AU2003246187A1 (en) * 2002-06-25 2004-01-06 Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING DIURETIC AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) Gamma ACTIAVTOR
WO2004013109A1 (ja) * 2002-08-02 2004-02-12 Sankyo Company, Limited レゾルシノール誘導体
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US20050026844A1 (en) 2003-04-03 2005-02-03 Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
CA2584342C (en) 2004-10-20 2013-04-30 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US7939528B2 (en) 2005-10-13 2011-05-10 Glaxosmithkline Llc Heterocycle compounds
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
TW201336497A (zh) 2007-02-08 2013-09-16 Daiichi Sankyo Co Ltd 噻唑啶二酮化合物之結晶型及其製法
EP2305673A4 (en) * 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
JPWO2010013769A1 (ja) * 2008-07-31 2012-01-12 第一三共株式会社 チアゾリジンジオン化合物の結晶及びその製造方法
WO2011065420A1 (ja) 2009-11-26 2011-06-03 第一三共株式会社 ６－置換－１－メチル－１ｈ－ベンズイミダゾール誘導体の製造法及びその製造中間体
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
WO2015160772A1 (en) * 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Tetrahydro-benzoimidazolyl modulators of tgr5
KR101480674B1 (ko) * 2014-07-03 2015-01-09 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496094B1 (ko) * 2014-07-04 2015-02-25 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496096B1 (ko) * 2014-07-17 2015-03-02 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2019034697A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5727290A (en) 1989-05-15 1990-12-18 Hyperion Catalysis International Surface treatment of carbon microfibers
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CZ282548B6 (cs) 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
WO1994015901A1 (en) 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
TW268952B (tr) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
JP3300869B2 (ja) 1993-08-09 2002-07-08 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
NO305987B1 (no) * 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
CZ261095A3 (en) * 1994-10-07 1996-04-17 Sankyo Co Oxime derivatives, process of their preparation, pharmaceutical composition containing thereof and their use
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
AU712187B2 (en) 1994-12-30 1999-10-28 Ligand Pharmaceuticals Incorporated Novel trienoic retinoid compounds and methods
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them
JPH09165371A (ja) * 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
BR9711098B1 (pt) 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
WO1998029120A1 (en) 1996-12-31 1998-07-09 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid x receptor selective agonists
ES2221203T3 (es) * 1997-10-08 2004-12-16 Sankyo Company Limited Compuesto heterociclico fusionado sustituido.

Also Published As

Publication number Publication date
HK1039940A1 (en) 2002-05-17
HK1039940B (zh) 2010-08-27
EP1167366B1 (en) 2010-05-05
NO321158B1 (no) 2006-03-27
CA2369971A1 (en) 2000-10-19
EP1167366A1 (en) 2002-01-02
CZ300691B6 (cs) 2009-07-15
NZ514662A (en) 2004-01-30
ZA200108174B (en) 2003-01-06
AU757729B2 (en) 2003-03-06
HUP0200996A3 (en) 2003-01-28
RU2221796C2 (ru) 2004-01-20
IL145759A0 (en) 2002-07-25
ES2343104T3 (es) 2010-07-23
PL351878A1 (en) 2003-06-30
BR0009594A (pt) 2002-06-04
NO20014847D0 (no) 2001-10-05
CN1162427C (zh) 2004-08-18
US6562849B1 (en) 2003-05-13
EP1167366A4 (en) 2003-05-28
IL145759A (en) 2009-12-24
TW550264B (en) 2003-09-01
ATE466861T1 (de) 2010-05-15
KR20010108458A (ko) 2001-12-07
HUP0200996A2 (hu) 2002-12-28
CN1354750A (zh) 2002-06-19
ID30498A (id) 2001-12-13
CZ20013592A3 (cs) 2002-03-13
MXPA01010108A (es) 2002-06-04
WO2000061581A1 (en) 2000-10-19
AU3670800A (en) 2000-11-14
NO20014847L (no) 2001-12-07
US20030078426A1 (en) 2003-04-24
DE60044342D1 (de) 2010-06-17
KR100588284B1 (ko) 2006-06-09

Similar Documents

Publication Publication Date Title
TR200103183T2 (tr) Amin türevi bileşimler
TR200200099T2 (tr) Th2 farklılaşma inhibitörleri
TR200201297T2 (tr) Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
TR200103335T2 (tr) Proteaz inhibitörleri olarak amin türevleri
ATE232520T1 (de) Imidazolidin-4-on derivate verwendbar als antikrebsmittel
TR200200587T2 (tr) Mantar öldürücü heterosiklik aromatik amitler ve bileşimleri, bunları kullanma ve hazırlama yöntemleri
TR200200701T2 (tr) Altı-elementli aromatik nitrojenli halka bileşimleri.
ATE271039T1 (de) Harnstoffderivate wirksam als muscarinrezeptor- antagonisten
TR200100075T2 (tr) 2-Kuinolon ihtiva eden farmasötik bileşimler
ATE223899T1 (de) Aryl-und hetaryl-sulfonamid derivate, deren herstellung und deren verwendung als endothelin- antagonisten
ATE248897T1 (de) Anthrachinonverbindungen und ihre derivate
ATE325105T1 (de) Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
TR200002481T2 (tr) Muskarinik Reseptör antegonistleri olarak 2-ariletil-(piperidin-4-ilmetil) amin türevleri
ATE257834T1 (de) Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
DE69739869D1 (de) Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation
ATE431349T1 (de) Variolinderivate als antikrebsmittel
TR200003220T2 (tr) İyi huylu prostat hiperplasianın tedavisinde yararlı olan yeni sübstitüe edilmiş piridino arilpiperazinler
TR200003884T2 (tr) N-Fenil-N'-Fenilpropilpiperazin türevleri ve bunların hazırlanma prosesi
ATE238274T1 (de) Naphthalin derivate
TR200200438T2 (tr) Tiazolidindion türevleri içeren farmasötik terkipler ve bu terkipleri hazırlama prosesi.
ATE273948T1 (de) Anthracene derivative als antitumormittel
TR200300359T4 (tr) İkameli yeni (dihidro)benzoksazin ve (dihidro)benzotiyazin türevleri bunların hazırlanma yöntemleri ve bunları içeren farmasötik bileşimler
TR200102315T2 (tr) Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2- on türevleri.
TR200402307T2 (tr) Beta-3 Adrenerjik reseptör agonistleri olarak aminoalkol türevleri.